Boehringer Ingelheim Animal Health | Horse Racing Free Tips

Thoroughbred Retirement Foundation, Boehringer Ingelheim Animal Health Team Up To Provide Vaccines

The Thoroughbred Retirement Foundation announced today that it has received more than 500 essential equine vaccines from Boehringer Ingelheim Animal Health. These vaccines will be used on retired Thoroughbred racehorses in the care of the Thoroughbred Retirement Foundation (TRF), the oldest and largest aftercare organization for retired Thoroughbreds in the United States.

“Helping organizations like the Thoroughbred Retirement Foundation is at the core of what we do at Boehringer Ingelheim Animal Health,” said Steve Boren, Vice President of the U.S. Livestock and Equine businesses at Boehringer Ingelheim Animal Health. “We are honored to support an organization that makes a difference in the lives of horses.”

As a global leader in equine health, Boehringer Ingelheim is committed to equine research and giving back to help communities understand, diagnose and prevent disease

“Equine veterinarians are one-of-a-kind caregivers who put the health and welfare of the horse above everything else,” Boren said. “We wanted to thank them for their passion and devotion both today and every day.”

“As soon as the TRF Team connected with the Boehringer Ingelheim equine team and realized the impact that their generous gift could make on our herd of TRF horses, we began connecting the team at Boehringer Ingelheim with our colleagues in the world of equine therapy and Thoroughbred aftercare,” said Anita Motion, TRF Board Member. “Our goal was to ensure that as many horses as possible benefit from this donation. We are so pleased to have played a part in extending Boehringer Ingelheim's gesture beyond our herd of 500 to thousands of other deserving horses in the care of charities across the United States.”

About the Thoroughbred Retirement Foundation

Founded in 1983, the Thoroughbred Retirement Foundation is a national organization devoted to saving Thoroughbred horses no longer able to compete at the racetrack from possible neglect, abuse, and slaughter. As the oldest Thoroughbred rescue in the country, the TRF provides sanctuary to retired Thoroughbreds throughout their lifetime.

Best known for its pioneering TRF Second Chances program, the organization provides incarcerated individuals with vocational training through its accredited equine care and stable management program. At seven correctional facilities and one new juvenile justice facility, this nationwide program offers second careers to its horses and a second chance at life for individuals upon release from these correctional programs. TRF cares for 500 rescued and retired Thoroughbreds at Second Chances prison farms and Sanctuary Farms across the country. The organization is funded entirely by private donations. The TRF is accredited by Thoroughbred Aftercare Alliance and has a Platinum rating with Guide Star.

For more information visit: http://www.trfinc.org/

The post Thoroughbred Retirement Foundation, Boehringer Ingelheim Animal Health Team Up To Provide Vaccines appeared first on Horse Racing News | Paulick Report.

Source of original post

TRF Recipient of 500 Equine Vaccines

The Thoroughbred Retirement Foundation (TRF) has been gifted more than 500 essential equine vaccines from Boehringer Ingelheim Animal Health. The vaccines will be used to innoculate retired horses in the TRF's care.

“Helping organizations like the Thoroughbred Retirement Foundation is at the core of what we do,” said Steve Boren, vice president of the U.S. livestock and equine businesses at Boehringer Ingelheim Animal Health. “We are honored to support an organization that makes a difference in the lives of horses.”

According to TRF board member Anita Motion, TRF is working with Boehringer Ingelheim Animal Health to provide vaccines for thousands of other horses as well.

“Our goal was to ensure that as many horses as possible benefit from this donation,” said Motion. “We are so pleased to have played a part in extending Boehringer Ingelheim's gesture beyond our herd of 500 to thousands of other deserving horses in the care of charities across the United States.”

The post TRF Recipient of 500 Equine Vaccines appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

First Inhaled Therapy For Severely Asthmatic Horses Launched In U.S.

Boehringer Ingelheim today announced the U.S. launch of the Aservo EquiHaler (ciclesonide inhalation spray), the first FDA-approved inhalant therapy for horses with severe equine asthma.

Developed after a decade of collaboration between Boehringer Ingelheim's human pharmaceutical and animal health businesses, the Aservo EquiHaler offers the promise of relief to thousands of horses that suffer from severe equine asthma, which affects 11 to 17 percent of horses.

Horses with severe equine asthma typically have clinical signs that include difficulty breathing, coughing and nasal discharge, which can have a significant impact on a horse's performance and quality of life. Over time, severely asthmatic horses may develop changes in the lung, which makes it difficult to breathe, even at rest.

“We understand the unique and inextricable link between animals and people. By delivering value through innovation, we strive to enhance the wellbeing of both and help shape the future direction of the industry,” said Caroline Belmont, Head of US Global Innovation and US Regulatory Affairs at Boehringer Ingelheim Animal Health. “We are focused on developing breakthrough therapeutics, like the Aservo EquiHaler, for animal disease areas with unmet needs to make a true impact in the lives of horses and their owners.”

The Aservo EquiHaler marks an industry first in equine medicine, as until now, there has been no FDA-approved inhalant therapy for use in horses with severe equine asthma. Severe equine asthma is an inflammatory disease of the lower airways caused by breathing in high concentrations of organic dust particles small enough to pass with air to the lower airways. Such particles are commonly found in hay and bedding.

Boehringer Ingelheim Animal Health used the Respimat inhaler, developed by the company's human pharmaceutical business, as a basis to develop the unique Soft Mist Technology of the Aservo EquiHaler, which is designed specifically for use in horses. The Aservo EquiHaler includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adapter that fits inside the nostril of the horse, allowing them to easily inhale the medicated mist into their lungs.

The active ingredient in the Aservo EquiHaler (ciclesonide inhalation spray) is ciclesonide, a glucocorticoid (steroid) that becomes activated in the lungs, which allows for the targeted delivery and activation of the medication. Studies in horses with severe asthma have demonstrated that administration of ciclesonide reversed airway obstruction associated with severe asthma, and to date, ciclesonide is the only glucocorticoid not associated with suppression of serum cortisol, a desired treatment outcome.

To learn more about Aservo EquiHaler, click here.

The post First Inhaled Therapy For Severely Asthmatic Horses Launched In U.S. appeared first on Horse Racing News | Paulick Report.

Source of original post